CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...